摘要
目的探讨不同剂量利培酮治疗首发精神分裂症的疗效及安全性。方法收集首发精神分裂症的患者60例按照住院单双号分为研究组和对照组,每组30例。研究组接受4 mg利培酮治疗,对照组接受6 mg利培酮治疗。结果两组治疗前阳性和阴性症状量表评分没有统计学意义(P>0.05),治疗3个月后差异有统计学意义(P<0.05);两组首发精神分裂症治疗有效率差异有统计学意义(P<0.05);两组的不良反应差异有统计学意义(P>0.05)。结论本次研究认为4 mg利培酮在提高首发精神分裂症治疗疗效的同时,未增加服药期间的不良反应,是较为安全的适宜剂量。
Objective To discuss the curative effect and safety of different dosage risperidone in treatment of first-episode schizophrenia. Methods 60 case patients with first-episode schizophrenia were divided into study group and control group according to hospitalization single and double sequence, 30 cases in each group. Study group received 4mg treatment with risperidone, while control group with 6 mg. To compare the positive and negative symptoms scale scores before and three months treatment between two groups. Results There had no significant differences in positive and negative symptoms scale scores before treatment（P〈0.05）, on the contrary there had significant differences after three months treatment（P〈0.05）. Treatment efficiency of two groups had statistically significance（P〈0.05）. The two group of adverse reaction was statistically significant（P〈0.05）. Conclusion This study considers that 4 mg risperidone in treatment of first-episode schizophrenia can improve curative effect, no adverse reaction increased during medication, it is more safety appropriate dosage.
出处
《中国医药指南》
2016年第11期87-88,共2页
Guide of China Medicine
关键词
利培酮
精神分裂症
疗效
Risperidone
Schizophrenia
Curative effect
